{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:48:28Z","timestamp":1793238508710,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.neuropharm.2004.11.008","type":"journal-article","created":{"date-parts":[[2005,2,2]],"date-time":"2005-02-02T13:46:55Z","timestamp":1107352015000},"page":"503-516","source":"Crossref","is-referenced-by-count":175,"title":["Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease"],"prefix":"10.1016","volume":"48","author":[{"given":"P.J.","family":"Hallett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.W.","family":"Dunah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ravenscroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Crossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.G.","family":"Standaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2004.11.008_bib1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1126\/science.1321498","article-title":"Syntaxin: a synaptic protein implicated in docking of synaptic vesicles at presynaptic active zones","volume":"257","author":"Bennett","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2004.11.008_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.expneurol.2003.12.012","article-title":"Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease","volume":"187","author":"Betarbet","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib5","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.1523\/JNEUROSCI.21-17-06853.2001","article-title":"Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease","volume":"21","author":"Bezard","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib6","first-page":"1034","article-title":"Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys","volume":"290","author":"Blanchet","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Pt 4","key":"10.1016\/j.neuropharm.2004.11.008_bib7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1046\/j.1469-7580.2000.19640527.x","article-title":"Synaptic organisation of the basal ganglia","volume":"196","author":"Bolam","year":"2000","journal-title":"J. Anat."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1460-9568.1992.tb00119.x","article-title":"Long-term potentiation in the striatum is unmasked by removing the voltage-dependent magnesium block of NMDA receptor channels","volume":"4","author":"Calabresi","year":"1992","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0278-5846(01)00237-8","article-title":"Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment","volume":"26","author":"Calon","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2004.11.008_bib10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib11","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S1471-1931(00)00018-5","article-title":"Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism","volume":"23","author":"Chase","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib12","first-page":"S122","article-title":"Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications","volume":"47","author":"Chase","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of parkinsonism-chronic treatment with L-DOPA","volume":"280","author":"Cotzias","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib14","doi-asserted-by":"crossref","first-page":"9585","DOI":"10.1016\/S0021-9258(18)98391-2","article-title":"Interaction with newly synthesized and retained proteins in the endoplasmic reticulum suggests a chaperone function for human integral membrane protein IP90 (calnexin)","volume":"268","author":"David","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0166-2236(94)90005-1","article-title":"Modulatory functions of neurotransmitters in the striatum - ACh\/dopamine\/NMDA interactions","volume":"17","author":"Di Chiara","year":"1994","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib16","first-page":"7","article-title":"The glutamate receptor ion channels","volume":"51","author":"Dingledine","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/mol.65.1.121","article-title":"Dopamine D1-dependent trafficking of striatal N-methyl-d-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32","volume":"65","author":"Dunah","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib18","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1523\/JNEUROSCI.21-15-05546.2001","article-title":"Dopamine D1 receptor-dependent trafficking of striatal NMDA glutamate receptors to the postsynaptic membrane","volume":"21","author":"Dunah","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1046\/j.1471-4159.2003.01744.x","article-title":"Subcellular segregation of distinct heteromeric NMDA glutamate receptors in the striatum","volume":"85","author":"Dunah","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib20","first-page":"342","article-title":"Alterations in subunit expression, composition and phosphorylation of striatal NMDA glutamate receptors in the rat 6-OHDA models of Parkinson's disease","volume":"57","author":"Dunah","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib21","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archneur.56.5.529","article-title":"Parkinson disease, the effect of levodopa, and the ELLDOPA trial. earlier vs later L-DOPA","volume":"56","author":"Fahn","year":"1999","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0969-8051(97)00224-2","article-title":"Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2-\u03b2-carbomethoxy-3-\u03b2-(4\u2032-methylphenyl) nortropane (PE2I)","volume":"25","author":"Guilloteau","year":"1998","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.nbd.2003.10.007","article-title":"Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys","volume":"15","author":"Hadj Tahar","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib24","unstructured":"Hallett, P.J., Dunah, A.W., Ravenscroft, P., Zhou, S., Bezard E., Crossman, A.R., Brotchie, J.M., Standaert, D.G., 2003. Striatal NMDA receptor subunit abundance and phosphorylation in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. 2003 Abstract Viewer\/Itinerary Planner. Society for Neuroscience, Washington, DC (online program 946.7)."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and use of NMDA receptor antagonists in Parkinson's disease","volume":"102","author":"Hallett","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib26","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1212\/WNL.61.6_suppl_3.S4","article-title":"The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications","volume":"61","author":"Jenner","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2004.11.008_bib27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/ana.410340413","article-title":"Toward an understanding of the role of glutamate in experimental Parkinsonism: agonist-sensitive sites in the basal ganglia","volume":"34","author":"Klockgether","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib28","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1126\/science.7569905","article-title":"Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95","volume":"269","author":"Kornau","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2004.11.008_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/(SICI)1096-9861(19980105)390:1<63::AID-CNE6>3.0.CO;2-O","article-title":"Expression of N-methyl-d-aspartate receptor subunit mRNA in the human neostriatum and globus pallidus","volume":"390","author":"Kosinski","year":"1998","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/(SICI)1096-9861(20000417)419:4<407::AID-CNE1>3.0.CO;2-I","article-title":"Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum","volume":"419","author":"K\u00fcppenbender","year":"2000","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0149-7634(96)00043-7","article-title":"Dopamine\/glutamate interactions in Parkinson's disease","volume":"21","author":"Lange","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib48","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/227680a0","article-title":"Cleavage of structural proteins during the assembly of the head of bacteriophage T4","volume":"227","author":"Laemmli","year":"1970","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2004.11.008_bib32","doi-asserted-by":"crossref","first-page":"20036","DOI":"10.1074\/jbc.270.34.20036","article-title":"Differential tyrosine phosphorylation of N-methyl-d-aspartate receptor subunits","volume":"270","author":"Lau","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.expneurol.2004.01.018","article-title":"Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease","volume":"187","author":"Loschmann","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1124\/mol.51.1.79","article-title":"The majority of N-methyl-d-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1\/NR2A\/NR2B)","volume":"51","author":"Luo","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib35","first-page":"125","article-title":"Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions","volume":"7","author":"Menegoz","year":"1995","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2004.11.008_bib36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/exnr.2000.7444","article-title":"Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease","volume":"165","author":"Nash","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib37","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/exnr.1998.6963","article-title":"Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat","volume":"155","author":"Nash","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0006-8993(98)01049-X","article-title":"Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration","volume":"813","author":"Oh","year":"1998","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0006-8993(99)01121-X","article-title":"Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits","volume":"821","author":"Oh","year":"1999","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib40","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410390505","article-title":"Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys","volume":"39","author":"Papa","year":"1996","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib41","doi-asserted-by":"crossref","first-page":"5283","DOI":"10.1523\/JNEUROSCI.1224-04.2004","article-title":"Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism","volume":"24","author":"Picconi","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/368144a0","article-title":"Changing subunit composition of heteromeric NMDA receptors during development","volume":"368","author":"Sheng","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2004.11.008_bib43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0166-2236(90)90106-K","article-title":"The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones","volume":"13","author":"Smith","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib44","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0169-328X(98)00293-9","article-title":"Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat","volume":"64","author":"Standaert","year":"1999","journal-title":"Brain. Res. Mol. Brain. Res."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cne.903430102","article-title":"Organization of N-methyl-d-aspartate glutamate receptor gene expression in the basal ganglia of the rat","volume":"343","author":"Standaert","year":"1994","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/exnr.2000.7374","article-title":"Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors","volume":"163","author":"Steece-Collier","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2004.11.008_bib47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.neuropharm.2004.03.011","article-title":"NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations hemi-parkinsonian rats","volume":"47","author":"Wessell","year":"2004","journal-title":"Neuropharmacology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390804003879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390804003879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T15:43:45Z","timestamp":1625413425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390804003879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0028390804003879"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2004.11.008","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}